Register your practice, schedule a sales rep visit, or order support materials with FIRMAGON Connect.

Sign Up Now

STOP TESTOSTERONE (T) AT ITS MAIN SOURCE

Firmagon® and leuprolide t suppression steps

Day 1: 52% achieved castrate levels vs 0% with leuprolide4

Day 3: 96% achieved castrate levels vs 0% with leuprolide4

Day 7: 99% of FIRMAGON patients achieved castrate levels4

By day 28, both groups achieved similar T levels4

Drag the slider below to see the difference between FIRMAGON® and leuprolide

Firmagon® and leuprolide t suppression steps

Binds to and directly blocks pituitary GnRH receptors2,3

1

Rapidly decreases T production at its main source2,3

  • By stopping T production quickly, prostate cancer cells are not stimulated to grow4

2

Binds to and stimulates pituitary LHRH receptors3

1

Promotes transient release of LH/FSH3

2

Significantly increases testosterone production2,3

3

Promotes testosterone surge by ≥50%5

  • Increased T can lead to worsening of symptoms of prostate cancer5
  • T can stimulate the growth of prostate cancer cells4,6

4

Continued administration leads to decreased LH/FSH3

5

Decreases T production3

6

Day 1: 52% achieved castrate levels vs 0% with leuprolide1

Day 3: 96% achieved castrate levels vs 0% with leuprolide1

Day 7: 99% of FIRMAGON patients achieved castrate levels1

By day 28, both groups achieved similar T levels1

Compare

T = testosterone.

Monthly Matters

Help make the most of your patient's treatment experience

Make the most of monthly visits. Help your patients feel connected to their therapy through the reassurance of regular treatment and progress check-ins. Ferring is here to help enhance this connection at every step.

One-month depot is ideal for my patients. They love to come in, get checked, and see their nurse practitioner to ask questions and get updated data about their condition.
Actual physician quote

REFERENCES: 1. Mottet N, Bellmunt J, Briers E, et al. Guidelines on Prostate Cancer. European Association of Urology; 2015. http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf. Accessed April 13, 2017. 2. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538. 3. Lupron Depot® [package insert]. North Chicago, IL: AbbVie Inc. 4. FIRMAGON® [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 5. American Cancer Society. Hormone therapy for prostate cancer; 2016. https://www.cancer.org/cancer/prostate-cancer/treating/hormone-therapy.html. Accessed July 11, 2017. 6. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1(4):293-297.

REFERENCES: 1. FIRMAGON® [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538. 3. Mottet N, Bellmunt J, Briers E, et al. Guidelines on Prostate Cancer. European Association of Urology; 2015. http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf. Accessed April 13, 2017. 4. American Cancer Society. Hormone therapy for prostate cancer; 2016. https://www.cancer.org/cancer/prostate-cancer/treating/hormone-therapy.html. Accessed July11, 2017. 5. Lupron Depot® [package insert]. North Chicago, IL: AbbVie Inc. 6. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1(4):293-297.